Last updated on February 2018

TCR-Redirected T Cell Infusions to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation

Brief description of study

Hepatocellular Carcinoma (HCC) recurrence rate is high among liver transplant patients, while treatment measures are limited. This study plans to recruit 10 subjects with Hepatitis B virus (HBV) related HCC after liver transplantation. The objective of the study is to assess the safety, tolerability and effectiveness of the HBV specific T cell receptor (HBV/TCR) redirected T cell in the target population.

Detailed Study Description

A single armed and open labelled trial in patients with hepatocellular carcinoma and HBV infection (HBsAg+) post liver transplantation. For patients who successfully match TCR histocompatibility locus antigen (HLA) restriction, escalating doses of HBV/TCR expressing autologous T cells will be infused. Tests will be done to confirmed safety and efficacy during the two-month treatment and observation period and twice each year of a follow up period up to five years.

Clinical Study Identifier: NCT02686372

Find a site near you

Start Over